This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Association for Molecular Pathology v. U.S Food and Drug Administration (FDA) The U.S. Food and Drug Administration (FDA) issued a final rule on May 6, 2024, to regulate laboratory-developed test (LDT) as medical devices and to oversee clinical laboratories as manufacturers of medical device. This rule would have increased reporting requirements by clinical laboratories, including registration for FDA premarket approval before launching new LDTs. AMP opposed this legislation and filed a lawsuit against the FDA in August 2024, citing concerns with the negative impact on patient access to LDTs and on laboratory innovation, as well as the expected increased costs of LDTs. On May 31, 2025, a U.S. federal court vacated this rule in favor of AMP and the American Clinical Laboratory Association, which had filed a separate lawsuit against the FDA. The court ruled that the regulation of LDTs as medical device “defies bedrock principles of statutory, common sense and longstanding industry practice” and that “Congress had already considered issues raised by LDTs in CLIA and had given the CMS regulatory authority over LDTs, not the FDA.” The FDA rule was officially withdrawn in September 2025.
Introduction of protecting group and mechanism of deprotection Senior undergraduate study notes on this subject, from Prof. Rizzo. A further set of study notes in tutorial form, with guidance and comments, from Profs. Grossman and Cammers. A user site excerpting the classic Greene and Wuts text regarding stability of a few key groups, from this reference's extensive tables. Organic-Reaction.com: Protecting Group Universität Marburg: Schutzgruppen in der organischen Synthesechemie (in German)
Alcohol is one of the oldest recreational drugs. The word "Alcohol" originates from the Arabic word al-kuhul, which refers to a fine metallic powder that was used to paint the eyelids darker. Alcoholic beverages have been produced since the Neolithic period, as early as 7000 BC in China. Alcohol was brewed as early as 7,000 to 6,650 BCE in northern China. The earliest evidence of winemaking was dated at 6,000 to 5,800 BCE in Georgia in the South Caucasus. Beer was likely brewed from barley as early as 13,000 years ago in the Middle East. Pliny the Elder wrote about the golden age of winemaking in Rome, the 2nd century BCE (200–100 BCE), when vineyards were planted.
Sources: en.wikipedia.org
Masterton and Slowinski used three criteria to describe the six elements commonly recognised as metalloids: metalloids have ionization energies around 200 kcal/mol (837 kJ/mol) and electronegativity values close to 2.0. They also said that metalloids are typically semiconductors, though antimony and arsenic (semimetals from a physics perspective) have electrical conductivities approaching those of metals. Selenium and polonium are suspected as not in this scheme, while astatine's status is uncertain. In this context, Vernon proposed that a metalloid is a chemical element that, in its standard state, has (a) the electronic band structure of a semiconductor or a semimetal; and (b) an intermediate first ionization potential "(say 750−1,000 kJ/mol)"; and (c) an intermediate electronegativity (1.9–2.2).
== Patents == This is a highly competitive area and a number of people claim patents in the field, most notably Alere (formerly Inverness Medical Innovations, now owned by Abbott) who own patents originally filed by Unipath. The US 6,485,982 patent, that has been litigated, expired in 2019. A number of other companies also hold patents in this arena. A group of competitors are challenging the validity of the patents. The original patent is apparently from 1988.
Globally, about 98 percent of soybean meal is used as animal feed. Of the US soybean production magnitude from 2010 through 2012, about 44 percent was exported as soybeans, and 53 percent was crushed in the US. Of the crushed tonnage, 19 percent was recovered as soybean oil and the remainder was recovered as soybean meal. Of the total US soybean tonnage produced, about 35 percent was fed to US livestock and poultry as soybean meal. Most of the remaining soybean meal produced in the US was exported. It has been estimated that, of soybean meal fed to animals in the US, 48 percent is fed to poultry, 26 percent to swine, 12 percent to beef cattle, 9 percent to dairy cattle, 3 percent is used in fish feed and about 2 percent in pet food. Although this implies that the tonnage of soybean meal fed to other species is relatively minor, such use is not unimportant. For example, for rapidly growing lambs on low-protein feeds, soybean meal can be an important supplement to ensure adequate protein intake, and partly because of its palatability, soybean meal is often recommended for use in starter rations when creep feeding lambs.
The Horizontal Working Party on Drugs (better known as Horizontal Drug Group or HDG) is a Council Working Party, a preparatory body of the Council of the European Union established in 1997, responsible for the lead and management of the work of the council and of the European Union (EU) on drug policy. The HDG meets monthly in Brussels's Europa building or in the Justus Lipsius building, and prepares all relevant legislation and political documents to be adopted by EU's Committee of Permanent Representatives (COREPER II) and subsequently by the Council, such as EU drugs strategies, action plans on drugs, and statements on drug-related aspects to be presented at international fora like the United Nations Commission on Narcotic Drugs. Since 2018, the HDG is also responsible to establish the imperative mandate for the vote on international scheduling by member state of the EU at the Commission on Narcotic Drugs. The HDG engages and closely collaborates with other EU institutions like the European Monitoring Centre for Drugs and Drug Addiction and Europol. There are frequent meetings of EU countries' national drugs coordinators held as part of HDG meetings. In addition, the HDG regularly meets with delegates from other regions and third countries within the EU's area of interest (Russia, Turkey, the Western Balkans, the United States within a so-called "Transatlantic Dialogue", Western Africa, Andes Community, and with countries from Latin America and the Caribbean within the "Technical Committee EU/LAC").
Sources: en.wikipedia.org
cell division The separation of an individual parent cell into two daughter cells by any process. Cell division generally occurs by a complex, carefully structured sequence of events involving the reorganization of the parent cell's internal contents, the physical cleavage of the cytoplasm and plasma membrane, and the even distribution of contents between the two resulting cells, so that each ultimately contains approximately half of the original cell's starting material. It usually implies reproduction via the replication of the parent cell's genetic material prior to division, though cells may also divide without replicating their DNA. In prokaryotic cells, binary fission is the primary form of cell division. In eukaryotic cells, asexual division occurs by mitosis and cytokinesis, while specific cell types reserved for sexual reproduction can additionally divide by meiosis.
Solutions of hypochlorites can be produced in-situ by electrolysis of an aqueous sodium chloride solution in both batch and flow processes. The composition of the resulting solution depends on the pH at the anode. In acid conditions the solution produced will have a high hypochlorous acid concentration, but will also contain dissolved gaseous chlorine, which can be corrosive; at a neutral pH the solution will be around 75% hypochlorous acid and 25% hypochlorite. Some of the chlorine gas produced will dissolve forming hypochlorite ions. Hypochlorites are also produced by the disproportionation of chlorine gas in alkaline solutions.
where ρ is the resistivity; i.e. the resistance R is inversely proportional to the cross section area S of the resistor. The reason why Poiseuille's law leads to a different formula for the resistance R is the difference between the fluid flow and the electric current. Electron gas is inviscid, so its velocity does not depend on the distance to the walls of the conductor. The resistance is due to the interaction between the flowing electrons and the atoms of the conductor. Therefore, Poiseuille's law and the hydraulic analogy are useful only within certain limits when applied to electricity. Both Ohm's law and Poiseuille's law illustrate transport phenomena.
== Cultivation == Successful cultivation requires warm to hot summers with high sunshine levels; even partial shade will reduce the yield substantially. It also prefers rich, well-drained soil. The seed is harvested by cutting the flower heads off the stalks when the seed is beginning to ripen. The seed heads are placed upside down in a paper bag and left in a warm, dry place for a week. The seeds then separate from the stems easily for storage in an airtight container. These plants, like their fennel and parsley relatives, often are eaten by black swallowtail caterpillars in areas where that species occurs. For this reason, they may be included in some butterfly gardens.
Gestational diabetes is a condition in which an individual without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms. Obesity increases the rate of pre-eclampsia, cesarean sections, and embryo macrosomia, as well as gestational diabetes. Babies born to individuals with poorly treated gestational diabetes are at increased risk of macrosomia, of having hypoglycemia after birth, and of jaundice. If untreated, diabetes can also result in stillbirth. Long term, children are at higher risk of being overweight and of developing type 2 diabetes. Gestational diabetes can occur during pregnancy because of insulin resistance or reduced production of insulin. Risk factors include being overweight, previously having gestational diabetes, a family history of type 2 diabetes, and having polycystic ovarian syndrome. Diagnosis is by blood tests. For those at normal risk, screening is recommended between 24 and 28 weeks' gestation. For those at high risk, testing may occur at the first prenatal visit. Maintaining a healthy weight and exercising before pregnancy assists in prevention. Gestational diabetes is treated with a healthy eating plan, exercise, medication (such as metformin), and sometimes insulin injections. Most people manage blood sugar with diet and exercise. Blood sugar testing among those affected is often recommended four times daily. Breastfeeding is recommended as soon as possible after birth. Gestational diabetes affects 3–9% of pregnancies, depending on the population studied.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.